Sign In
Buy ABCL
AbCellera Biologics Earnings Calls
| Release date | May 11, 2026 |
| EPS estimate | -$0.220 |
| EPS actual | -$0.140 |
| EPS Surprise | 36.36% |
| Revenue estimate | 5.412M |
| Revenue actual | 8.315M |
| Revenue Surprise | 53.63% |
| Release date | Feb 24, 2026 |
| EPS estimate | -$0.180 |
| EPS actual | -$0.0300 |
| EPS Surprise | 83.33% |
| Revenue estimate | 6.673M |
| Revenue actual | 44.9M |
| Revenue Surprise | 572.89% |
| Release date | Nov 06, 2025 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.190 |
| EPS Surprise | -11.76% |
| Revenue estimate | 6.312M |
| Revenue actual | 8.955M |
| Revenue Surprise | 41.87% |
| Release date | Aug 07, 2025 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.120 |
| EPS Surprise | 29.41% |
| Revenue estimate | 6.36M |
| Revenue actual | 17.084M |
| Revenue Surprise | 168.63% |
Last 4 Quarters for AbCellera Biologics
Below you can see how ABCL performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 07, 2025 |
| Price on release | $4.24 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.120 |
| EPS surprise | 29.41% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $4.24 |
| Aug 04, 2025 | $4.34 |
| Aug 05, 2025 | $4.36 |
| Aug 06, 2025 | $4.12 |
| Aug 07, 2025 | $4.24 |
| Aug 08, 2025 | $4.25 |
| Aug 11, 2025 | $4.50 |
| Aug 12, 2025 | $4.27 |
| Aug 13, 2025 | $4.58 |
| 4 days before | 0% |
| 4 days after | 8.02% |
| On release day | 0.236% |
| Change in period | 8.02% |
| Release date | Nov 06, 2025 |
| Price on release | $4.53 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.190 |
| EPS surprise | -11.76% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $5.55 |
| Nov 03, 2025 | $5.37 |
| Nov 04, 2025 | $4.87 |
| Nov 05, 2025 | $4.69 |
| Nov 06, 2025 | $4.53 |
| Nov 07, 2025 | $3.91 |
| Nov 10, 2025 | $4.03 |
| Nov 11, 2025 | $4.01 |
| Nov 12, 2025 | $3.97 |
| 4 days before | -18.38% |
| 4 days after | -12.36% |
| On release day | -13.69% |
| Change in period | -28.47% |
| Release date | Feb 24, 2026 |
| Price on release | $3.22 |
| EPS estimate | -$0.180 |
| EPS actual | -$0.0300 |
| EPS surprise | 83.33% |
| Date | Price |
|---|---|
| Feb 18, 2026 | $3.13 |
| Feb 19, 2026 | $3.22 |
| Feb 20, 2026 | $3.04 |
| Feb 23, 2026 | $3.03 |
| Feb 24, 2026 | $3.22 |
| Feb 25, 2026 | $3.19 |
| Feb 26, 2026 | $3.59 |
| Feb 27, 2026 | $3.61 |
| Mar 02, 2026 | $3.82 |
| 4 days before | 2.88% |
| 4 days after | 18.63% |
| On release day | -0.93% |
| Change in period | 22.04% |
| Release date | May 11, 2026 |
| Price on release | $5.25 |
| EPS estimate | -$0.220 |
| EPS actual | -$0.140 |
| EPS surprise | 36.36% |
| Date | Price |
|---|---|
| May 05, 2026 | $4.66 |
| May 06, 2026 | $5.04 |
| May 07, 2026 | $4.82 |
| May 08, 2026 | $5.24 |
| May 11, 2026 | $5.25 |
| May 12, 2026 | $4.95 |
| May 13, 2026 | $4.77 |
| May 14, 2026 | $4.40 |
| May 15, 2026 | $4.09 |
| 4 days before | 12.66% |
| 4 days after | -22.10% |
| On release day | -5.71% |
| Change in period | -12.23% |
AbCellera Biologics Earnings Call Transcript Summary of Q1 2026
AbCellera reported encouraging interim Phase I data for ABCL635 (an anti-NK3R antibody for vasomotor symptoms). The single ascending dose data showed favorable tolerability (no serious or liver-related adverse events), linear PK with ~24-day half-life supporting once-monthly subcutaneous dosing, and sustained, dose-dependent target engagement (testosterone, LH, FSH suppression) that meets or exceeds published levels for the approved small-molecule NK3R antagonist fezolinetant. Based on these data, AbCellera advanced ABCL635 into Phase II (600 mg single dose vs placebo; primary endpoint at 4 weeks) with topline results expected in Q3 2026. The company reiterated pipeline progress: a Phase I topline readout for ABCL575 expected in Q4 2026, IND-enabling work for ABCL688 and ABCL386 with clinical starts targeted toward 2027, and selection of an additional development candidate planned. Financially, AbCellera finished Q1 2026 with approximately $531M in cash/cash equivalents and $125M of available committed government funding (about $655M total available liquidity), R&D spending increased as internal programs ramp, and the company expects research fee revenue to trend lower as focus shifts to internal assets.
